Vincent Angotti Net Worth

The estimated Net Worth of Vincent J. Angotti is at least $2.21 million dollars as of 13 December 2023. Mr. Angotti owns over 10,000 units of Acelrx Pharmaceuticals Inc stock worth over $87,552 and over the last 8 years he sold ACRX stock worth over $0. In addition, he makes $2,125,050 as Chief Executive Officer et Director at Acelrx Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Angotti ACRX stock SEC Form 4 insiders trading

Vincent has made over 11 trades of the Acelrx Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ACRX stock worth $7,300 on 13 December 2023.

The largest trade he's ever made was buying 46,400 units of Acelrx Pharmaceuticals Inc stock on 7 June 2022 worth over $10,208. On average, Vincent trades about 4,613 units every 82 days since 2017. As of 13 December 2023 he still owns at least 101,805 units of Acelrx Pharmaceuticals Inc stock.

You can see the complete history of Mr. Angotti stock trades at the bottom of the page.

Vincent Angotti biography

Vincent J. Angotti serves as Chief Executive Officer, Director of the Company. From 2015 to 2016, Mr. Angotti was Chief Executive Officer and Director of XenoPort, Inc., a biopharmaceutical company that was acquired by Arbor Pharmaceuticals, LLC in 2016. Prior to that, from 2008 to 2015, Mr. Angotti held various roles at Xenoport, including Executive VP and Chief Operating Officer from 2012 to 2015, and Senior Vice President and Chief Commercialization Officer from 2008 to 2012. Prior to joining XenoPort, from 2001 to 2008, Mr. Angotti held several senior sales and marketing positions at Reliant Pharmaceuticals, Inc., a pharmaceutical company that was acquired by GlaxoSmithKline in 2007, the most recent of which was senior vice president of sales and marketing. Mr. Angotti began his career in the life sciences industry at Novartis Pharmaceuticals Corp., where he worked from 1991 until 2001 in sales and operations positions, most recently as executive director, field operations. He holds a Bachelor of Science with a concentration in business management from Cornell University and a Masters of Business Administration with honors from Columbia University. Mr. Angotti’s role as our Chief Executive Officer, his business expertise and his prior leadership roles in pharmaceutical companies provides him with the qualifications and skills to serve as a director.

What is the salary of Vincent Angotti?

As the Chief Executive Officer et Director of Acelrx Pharmaceuticals Inc, the total compensation of Vincent Angotti at Acelrx Pharmaceuticals Inc is $2,125,050. There are no executives at Acelrx Pharmaceuticals Inc getting paid more.

How old is Vincent Angotti?

Vincent Angotti is 52, he's been the Chief Executive Officer et Director of Acelrx Pharmaceuticals Inc since 2017. There are 12 older and 1 younger executives at Acelrx Pharmaceuticals Inc. The oldest executive at Acelrx Pharmaceuticals Inc is Lawrence G. Hamel, 69, who is the Consultant.

What's Vincent Angotti's mailing address?

Vincent's mailing address filed with the SEC is C/O ACELRX PHARMACEUTICALS, INC., 1850 GATEWAY DRIVE, SUITE 175, SAN MATEO, CA, 94404.

Insiders trading at Acelrx Pharmaceuticals Inc

Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over $25,363,406 worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth $26,783,172 . The most active insiders traders include Advisors Llcperceptive Life..., Advisors Llcedelman Josephp... et Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $109,939. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth $7,300.

What does Acelrx Pharmaceuticals Inc do?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Complete history of Mr. Angotti stock trades at Acelrx Pharmaceuticals Inc

Acelrx Pharmaceuticals Inc executives and stock owners

Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Vincent Angotti,
  Chief Executive Officer, Director
• Pamela Palmer,
  Co-Founder, Director, Chief Medical Officer
• Raffi Asadorian,
  Chief Financial Officer
• Vincent J. Angotti,
  CEO & Director
• Badri Dasu,
  Chief Engineering Officer
• Dr. Pamela Pierce Palmer,
  Co-Founder, Chief Medical Officer & Director
• Raffi Mark Asadorian,
  Chief Financial Officer
• Anil N. Dasu,
  Chief Engineering Officer
• Adrian Adams,
  Independent Chairman of the Board
• Mark Edwards,
  Independent Director
• Stephen Hoffman,
  Independent Director
• Mark Wan,
  Independent Director
• Richard Afable,
  Independent Director
• Howard Rosen,
  Independent Director
• Lawrence G. Hamel,
  Consultant
• C Steven Hoffman,
  Director
• Advisors Llcperceptive Life...,
  
• Lawrence G Hamel,
  Chief Development Officer
• Timothy E Morris,
  Chief Financial Officer
• Jane Wright Mitchell,
  Chief Legal Officer
• Advisors Llcedelman Josephp...,
  
• John G. Saia,
  General Counsel and Secretary
• Marina Bozilenko,
  Director
• David Chung,
  Chief Commercial Officer
• Venture Partners Qualified ...,
  
• Mark Ajaeger Wilfred Ethree...,
  
• James H Welch,
  Chief Financial Officer
• Thomas A Schreck,
  Director
• Guy P Nohra,
  Director
• Mark Ajaeger Wilfred Ethree...,
  
• Venture Partners Qualified ...,
  
• Richard King,
  President and CEO
• Arch Management Iii Llcwan ...,
  
• Arch Management Iv, L.L.C.T...,
  
• Iv, L.P.Nohra Guy Pjanney D...,
  
• Mark Ajaeger Wilfred Ethree...,
  
• Jill Marie Broadfoot,
  Director